PURPOSE OF REVIEW: Understanding the mechanisms by which castration-resistant prostate cancer (CRPC) progresses provides an opportunity to identify novel therapeutic strategies to treat this disease. This understanding has led to approaches to attack prostate cancer's androgen axis in unique ways. This review will examine the classes of novel therapies for androgen axis blockade in CRPC, with a particular focus on the unique characteristics of drugs in various stages of clinical development. RECENT FINDINGS: The success of abiraterone and enzalutamide has stimulated multiple investigations into novel approaches to attack the androgen-signaling pathway. Drugs under development include cytochrome P17 inhibitors with 17,20-lyase specificity, androgen receptor antagonists that are active against mutated and constitutively active splice variant forms of the protein, androgen receptor degraders, and bromodomain/bromodomain extra-terminal inhibitors that prevent chromatin binding of activated receptors. The clinical development of several of these experimental agents is reviewed. SUMMARY: Given the unique mechanisms of action for drugs in development, and the possibility that the novel agents may be active in the setting of common resistance mechanisms, treatment options for patients are likely to expand greatly in the coming years. Future studies should prioritize combinations of agents with unique mechanisms of action to optimize outcomes for patients, and should rely on precision-medicine approaches to target known molecular alterations.
PURPOSE OF REVIEW: Understanding the mechanisms by which castration-resistant prostate cancer (CRPC) progresses provides an opportunity to identify novel therapeutic strategies to treat this disease. This understanding has led to approaches to attack prostate cancer's androgen axis in unique ways. This review will examine the classes of novel therapies for androgen axis blockade in CRPC, with a particular focus on the unique characteristics of drugs in various stages of clinical development. RECENT FINDINGS: The success of abiraterone and enzalutamide has stimulated multiple investigations into novel approaches to attack the androgen-signaling pathway. Drugs under development include cytochrome P17 inhibitors with 17,20-lyase specificity, androgen receptor antagonists that are active against mutated and constitutively active splice variant forms of the protein, androgen receptor degraders, and bromodomain/bromodomain extra-terminal inhibitors that prevent chromatin binding of activated receptors. The clinical development of several of these experimental agents is reviewed. SUMMARY: Given the unique mechanisms of action for drugs in development, and the possibility that the novel agents may be active in the setting of common resistance mechanisms, treatment options for patients are likely to expand greatly in the coming years. Future studies should prioritize combinations of agents with unique mechanisms of action to optimize outcomes for patients, and should rely on precision-medicine approaches to target known molecular alterations.
Authors: Jing Lu; Yimin Qian; Martha Altieri; Hanqing Dong; Jing Wang; Kanak Raina; John Hines; James D Winkler; Andrew P Crew; Kevin Coleman; Craig M Crews Journal: Chem Biol Date: 2015-06-04
Authors: Irfan A Asangani; Vijaya L Dommeti; Xiaoju Wang; Rohit Malik; Marcin Cieslik; Rendong Yang; June Escara-Wilke; Kari Wilder-Romans; Sudheer Dhanireddy; Carl Engelke; Mathew K Iyer; Xiaojun Jing; Yi-Mi Wu; Xuhong Cao; Zhaohui S Qin; Shaomeng Wang; Felix Y Feng; Arul M Chinnaiyan Journal: Nature Date: 2014-04-23 Impact factor: 49.962
Authors: Sarah A Loddick; Sarah J Ross; Andrew G Thomason; David M Robinson; Graeme E Walker; Tom P J Dunkley; Sandra R Brave; Nicola Broadbent; Natalie C Stratton; Dawn Trueman; Elizabeth Mouchet; Fadhel S Shaheen; Vivien N Jacobs; Marie Cumberbatch; Joanne Wilson; Rhys D O Jones; Robert H Bradbury; Alfred Rabow; Luke Gaughan; Chris Womack; Simon T Barry; Craig N Robson; Susan E Critchlow; Stephen R Wedge; A Nigel Brooks Journal: Mol Cancer Ther Date: 2013-07-16 Impact factor: 6.261
Authors: Charlie D Chen; Derek S Welsbie; Chris Tran; Sung Hee Baek; Randy Chen; Robert Vessella; Michael G Rosenfeld; Charles L Sawyers Journal: Nat Med Date: 2003-12-21 Impact factor: 53.440
Authors: Karim Fizazi; Christophe Massard; Petri Bono; Robert Jones; Vesa Kataja; Nicholas James; Jorge A Garcia; Andrew Protheroe; Teuvo L Tammela; Tony Elliott; Leena Mattila; John Aspegren; Annamari Vuorela; Peter Langmuir; Mika Mustonen Journal: Lancet Oncol Date: 2014-06-25 Impact factor: 41.316
Authors: Jae-Kyung Myung; Carmen A Banuelos; Javier Garcia Fernandez; Nasrin R Mawji; Jun Wang; Amy H Tien; Yu Chi Yang; Iran Tavakoli; Simon Haile; Kate Watt; Iain J McEwan; Stephen Plymate; Raymond J Andersen; Marianne D Sadar Journal: J Clin Invest Date: 2013-06-03 Impact factor: 14.808
Authors: A O'Donnell; I Judson; M Dowsett; F Raynaud; D Dearnaley; M Mason; S Harland; A Robbins; G Halbert; B Nutley; M Jarman Journal: Br J Cancer Date: 2004-06-14 Impact factor: 7.640
Authors: Anastasia Wyce; Yan Degenhardt; Yuchen Bai; BaoChau Le; Susan Korenchuk; Ming-Chih Crouthame; Charles F McHugh; Robert Vessella; Caretha L Creasy; Peter J Tummino; Olena Barbash Journal: Oncotarget Date: 2013-12
Authors: Joo Hyoung Lee; Minsung Kang; Hong Wang; Gurudatta Naik; James A Mobley; Guru Sonpavde; W Timothy Garvey; Victor M Darley-Usmar; Selvarangan Ponnazhagan Journal: FASEB J Date: 2017-01-09 Impact factor: 5.191
Authors: Clement G Yedjou; Ariane T Mbemi; Felicite Noubissi; Solange S Tchounwou; Nole Tsabang; Marinelle Payton; Lucio Miele; Paul B Tchounwou Journal: Nutrients Date: 2019-02-04 Impact factor: 5.717